Quarterly ResultMay 12, 2026, 04:13 PM
Tenax Therapeutics Q1 Net Loss $(15.7)M; R&D Expenses Up 103%
AI Summary
Tenax Therapeutics reported a net loss of $(15.7) million for the first quarter of 2026, an increase from $(10.4) million in the prior year, primarily driven by a 103% rise in research and development expenses to $11.5 million. Despite increased operating losses, the company's cash and cash equivalents grew to $118.8 million by March 31, 2026, bolstered by $30.5 million from warrant exercises. The company also announced the appointment of Thomas R. Staab, II as its new CFO and confirmed sufficient liquidity to fund operations through the first quarter of 2028, alongside achieving target enrollment for its Phase 3 LEVEL study.
Key Highlights
- Net loss for Q1 2026 increased to $(15.7) million from $(10.4) million in Q1 2025.
- Research and development expenses rose 103% to $11.5 million in Q1 2026 from $5.7 million in Q1 2025.
- Cash and cash equivalents stood at $118.8 million as of March 31, 2026, up from $97.6 million at December 31, 2025.
- Net cash used in operating activities was $(9.3) million for Q1 2026, compared to $(7.0) million for Q1 2025.
- Net cash provided by financing activities was $30.5 million for Q1 2026, including $30.5 million from warrant exercises.
- The company appointed Thomas R. Staab, II as Chief Financial Officer, effective May 11, 2026.
- The Phase 3 LEVEL study achieved its target enrollment of 230 patients in March 2026.
- Existing cash and cash equivalents, plus subsequent warrant exercises, are expected to fund operations through Q1 2028.
Price Impact
More from TENX